| Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer LA Hildebrand, CJ Pierce, M Dennis, M Paracha, A Maoz Cancers 13 (3), 391, 2021 | 65 | 2021 |
| Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA‐negative Hispanics with … JN Weitzel, SL Neuhausen, A Adamson, S Tao, C Ricker, A Maoz, ... Cancer 125 (16), 2829-2836, 2019 | 52 | 2019 |
| The Crohn's-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer A Maoz, M Dennis, JK Greenson Frontiers in Immunology, 1884, 2019 | 49 | 2019 |
| T-Cell Transfer Therapy Targeting Mutant KRAS. A Maoz, G Rennert, SB Gruber The New England journal of medicine 376 (7), e11, 2017 | 40* | 2017 |
| Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review A Maoz, K Matsuo, MA Ciccone, S Matsuzaki, M Klar, LD Roman, ... Cancers 12 (6), 1398, 2020 | 32 | 2020 |
| Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer K Matsuo, S Matsuzaki, DJ Nusbaum, A Maoz, K Oda, M Klar, LD Roman, ... Gynecologic Oncology 160 (1), 32-39, 2021 | 25 | 2021 |
| Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis R Sanz-Pamplona, M Melas, A Maoz, SL Schmit, H Rennert, F Lejbkowicz, ... PLoS medicine 17 (9), e1003292, 2020 | 25 | 2020 |
| Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature MA Ciccone, A Maoz, JK Casabar, H Machida, S Mabuchi, K Matsuo Expert opinion on investigational drugs 25 (7), 781-796, 2016 | 16 | 2016 |
| Highly multiplexed imaging mass cytometry allows visualization of tumor and immune cell interactions of the tumor microenvironment in FFPE tissue sections M Singh, P Chaudhry, E Gerdtsson, A Maoz, W Cozen, J Hicks, P Kuhn, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 2751 …, 2017 | 13 | 2017 |
| Bortezomib ocular toxicities: Outcomes with ketotifen M Dennis, A Maoz, D Hughes, V Sanchorawala, JM Sloan, S Sarosiek American journal of hematology 94 (3), E80-E82, 2019 | 11 | 2019 |
| Increased high-sensitivity troponin-T levels are associated with mortality after ischemic stroke A Maoz, S Rosenberg, RR Leker Journal of Molecular Neuroscience 57, 160-165, 2015 | 10 | 2015 |
| Emerging serine-threonine kinase inhibitors for treating ovarian cancer A Maoz, MA Ciccone, S Matsuzaki, RL Coleman, K Matsuo Expert Opinion on Emerging Drugs 24 (4), 239-253, 2019 | 7 | 2019 |
| Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden V Florou, CS Floudas, A Maoz, AR Naqash, C Norton, AC Tan, ES Sokol, ... Journal for Immunotherapy of Cancer 11 (8), 2023 | 5 | 2023 |
| Treatment disparities in minority groups with multiple myeloma at a safety-net hospital M Dennis, A Maoz, D Cirstea, A Patel, A Lerner, S Sarosiek Leukemia & Lymphoma 61 (10), 2507-2510, 2020 | 5 | 2020 |
| Inhibition of poly (ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells MA Ciccone, CL Adams, C Bowen, T Thakur, C Ricker, JO Culver, A Maoz, ... Gynecologic Oncology 159 (3), 869-876, 2020 | 4 | 2020 |
| Haemodialysis-associated thrombocytopenia: interactions among the immune system, membranes and sterilisation methods F Batalini, GF Aleixo, A Maoz, S Sarosiek BMJ Case Reports CP 12 (9), e229594, 2019 | 4 | 2019 |
| Factors affecting the rates of adherence to surveillance recommendations for incidental pancreatic cystic lesions in a large urban safety net hospital A Canakis, A Maoz, JN Tkacz, C Huang BMJ Open Gastroenterology 7 (1), e000430, 2020 | 3 | 2020 |
| Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction K Vaccaro, J Allen, TW Whitfield, A Maoz, S Reeves, J Velarde, D Yang, ... The Journal of Clinical Investigation, 2024 | 2 | 2024 |
| Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer YY Tsai, C Qu, JD Bonner, R Sanz-Pamplona, SS Lindsey, M Melas, ... Frontiers in Immunology 14, 1268117, 2023 | 2 | 2023 |
| STK11/TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile. AR Naqash, CS Floudas, A Maoz, J Xiu, Y Baca, J Zeng, C Kim, J Judd, ... Journal of Clinical Oncology 39 (15_suppl), 9087-9087, 2021 | 2 | 2021 |
Gad Rennertcarmel medical center, technion, clalit, haifa, israelVerified email at tx.technion.ac.il
